AG真人官方

Citigroup Global Markets Holdings Inc., fully guaranteed by Citigroup Inc., has filed Product Supplement No. ES-01-10 to its March 7 2023 base prospectus and July 10 2025 prospectus supplement for future issuances of Equity-Linked Securities (ELKS), Callable Yield Securities, or other similarly structured notes (collectively, the 鈥渟ecurities鈥�). These medium-term senior notes (Series N) provide fixed coupon payments but do not assure repayment of principal. Repayment at maturity depends on the performance of one or more 鈥淯nderlying Shares鈥� 鈥� individual equities, American depositary shares (ADSs), exchange-traded funds (ETFs) or, in some structures, the worst performer among multiple underlyings.

Key structural terms (set in each future pricing supplement):

• Coupon rate and payment schedule.
• Definition of 鈥淒ownside Event,鈥� equity ratio, initial share price and downside threshold price.
• Choice of valuation method (closing price vs. intra-day trading price) and observation window (single-day, daily, or period-based testing).
• Issuer call right on specified dates (if applicable).
• Issuer option to settle in cash instead of delivering shares.

Principal risks highlighted:

• Loss of up to 100 % of principal if a downside event occurs; investors receive underlying shares (or cash equivalent) likely worth less than par.
• No participation in upside appreciation; return is capped at coupons.
• Credit risk of both Citigroup Global Markets Holdings Inc. and Citigroup Inc.; securities are senior unsecured obligations.
• Generally no exchange listing, hence limited secondary liquidity; potential reliance on Citigroup Global Markets as sole market-maker.
• Complex U.S. tax treatment; IRS may challenge issuer鈥檚 assumptions, and Section 871(m) withholding may apply to non-U.S. holders.
• Broad calculation-agent discretion (an affiliate of the issuer) in determining prices, adjustments and market-disruption resolutions, creating potential conflicts of interest.

The document incorporates extensive risk disclosures covering volatility sensitivity, dividend dilution, market-disruption events, delisting scenarios, ETF-specific considerations, emerging-market exposure, and tax uncertainties. Investors are directed to read this supplement together with the base prospectus, the July 10 2025 prospectus supplement, and the eventual pricing supplement for each issuance before investing.

Form 4 overview: On 23-Jun-2025 Delta Air Lines (DAL) filed a Form 4 disclosing two insider transactions by director Sergio Rial.

• 18-Jun-2025: 1,212 shares were withheld (Code F) at $47.56 to cover taxes on a 2024 restricted-stock vesting; transaction approved by the Personnel & Compensation Committee and exempt under Rule 16b-3.
• 20-Jun-2025: 4,240 restricted shares were granted (Code A) as the annual $200,000 equity award to non-employee directors. Because 19-Jun was a federal holiday, the grant date shifted to the next trading day; the award is likewise Rule 16b-3 exempt.

Following these movements Mr. Rial directly owns 36,069 DAL shares, a net increase of 3,028 shares (鈮�9.2%) versus the pre-event balance. No derivative securities were reported.

The filing is routine, compensation-related, and introduces no new information about Delta鈥檚 operations, earnings or strategy.

On June 30, 2025, Indivior PLC (Nasdaq/LSE: INDV) filed a Form 8-K to furnish information under Item 7.01 (Regulation FD). The company reported, via an attached press release (Exhibit 99.1), that its ordinary shares have been selected for inclusion in both the U.S. Russell 2000 and Russell 3000 indexes. The filing contains no financial statements, earnings figures, or operational updates; it strictly communicates the index-membership development. While purely informational, index inclusion typically broadens a company鈥檚 investor base and can enhance share liquidity because passive funds that track the Russell family of indexes are required to purchase constituent stocks. No additional material events, transactions, or strategic changes are disclosed in this report.

Form 4 filing overview 鈥� Delta Air Lines, Inc. (DAL)

Non-executive board chair David S. Taylor reported the annual equity grant approved by Delta鈥檚 board on 19 June 2025 and deemed granted on the next trading day, 20 June 2025, in accordance with the company鈥檚 Equity Award Grant Policy. The award consists of 6,780 shares of Delta common stock, designated as a restricted stock award exempt under Rule 16b-3(d)(1). The filing shows the shares were acquired (Transaction code 鈥淎鈥�) and directly increase the director鈥檚 personal holdings.

Post-transaction holdings

• Direct ownership: 23,240 shares following the award.
• Indirect ownership: 99,480 shares held in a Grantor Retained Annuity Trust (GRAT) established for the benefit of the reporting person鈥檚 adult children, for which Mr. Taylor serves as trustee and sole annuity recipient.

The restricted stock award is valued at $320,000, reflecting Delta鈥檚 annual equity compensation for its non-executive chair. No derivative securities were involved, and no dispositions occurred. The filing was signed on 23 June 2025 by an attorney-in-fact on Mr. Taylor鈥檚 behalf.

No other transactions, option exercises, or changes in indirect ownership were reported. Given the scale of Delta鈥檚 outstanding share count, the acquisition is routine board compensation rather than a market-moving insider purchase.

The Form 144 filing indicates that an affiliate of KALA BIO, Inc. (KALA) plans to sell up to 13,227 shares of common stock through E*TRADE Financial on or about 24 June 2025. Using the filing鈥檚 stated market value of $53,040.27, the proposed sale represents roughly 0.2 % of the company鈥檚 6,452,398 shares outstanding, suggesting limited dilution or market impact. The shares stem from a restricted-stock-unit (RSU) vesting that occurred the same day. The filer previously sold 10,866 shares for $40,638.84 earlier in June, signalling a pattern of modest insider dispositions. Form 144 is only a notice; the shares may or may not ultimately be sold, but it provides investors an early look at potential insider activity. No new operational, earnings, or strategic information about KALA BIO is furnished in this document.

Form 4 overview: Chief Scientific Officer David Bredt sold 8,500 shares of Rapport Therapeutics (RAPP) on 16-Jun-2025 at a weighted-average price of $11.0026, generating roughly $93,500 in proceeds. The trade was executed under a pre-arranged Rule 10b5-1 plan adopted 12-Dec-2024.

The disposition lowered Bredt鈥檚 direct holdings to 443,642 common shares and involved no derivative securities. No other insiders or transaction types were disclosed.

Investor takeaway: The sale represents about 1.9 % of the executive鈥檚 stake鈥攕mall relative to his remaining position. Because it was scheduled under 10b5-1, signalling risk is limited and market impact should be largely neutral.

Delta Air Lines (DAL) 鈥� Form 4 filing dated 23 Jun 2025 documents an insider equity grant to director Michael P. Huerta.

• Transaction date: 20 Jun 2025 (next trading day after the 19 Jun 2025 federal holiday).
• Securities acquired: 4,240 shares of Delta common stock designated as an annual restricted stock award for non-employee directors.
• Grant value: Board-approved award is valued at $200,000 (per explanatory footnote); price per share is not disclosed.
• Post-transaction ownership: Huerta now beneficially owns 35,745 Delta shares, held directly.
• The acquisition was made under Rule 16b-3(d)(1), providing an exemption for director compensation awards.

No derivative securities were reported, and there is no indication of open-market buying or selling. The filing is routine, reflecting annual board compensation and modestly increasing insider alignment without signalling a strategic shift.

Delta Air Lines, Inc. (DAL) 鈥� Form 4 insider filing

Non-employee director David G. DeWalt received an annual restricted stock award of 4,240 DAL common shares on 20 June 2025. The grant, valued at approximately $200,000 and approved by the board on 19 June (a federal holiday), was effected the next trading day per Delta鈥檚 equity-grant policy. Classified as an acquisition (code 鈥淎鈥�) exempt under Rule 16b-3, the award lifts DeWalt鈥檚 direct beneficial stake to 83,490 shares. No shares were sold or transferred.

This is a routine equity-based compensation event for board members and is not expected to materially influence Delta鈥檚 share count, cash flows, or market sentiment.